A country that has prevailed vs B.1.1.7
Those states that were in trouble?
No longer the case. In descent or flat.
Overall cases are down 30%, hospitalizations and deaths down ~10% over the past 2 weeks
Here's the lineage (variant) map of the US through the pandemic, based on 360,000 sequences. Dark blue is B.1.1.7 that became dominant throughout. The only other major variant competing now is P.1 (Brazil) at 2% prevalence outbreak.info/location-repor…
By getting nearly 150 million Americans vaccinated, the US averted pronounced surges, the worst seen in many countries, such as the UK and Israel, and throughout most of Europe
Instead, we just had a B.1.1.7 bump.
Had Americans not come together to get all the vaccinations done, including many days getting shots for well over 1% of the whole population, this would not have been the case.
But we've still got work to do. With >50,000 new cases a day we are nowhere near containment like the UK and Israel. That 5-15X gap is associated with a 10-15% more population vaccinated. If we can get that done, summer will be a time to celebrate.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We're learning how to control the immune response, like a rheostat, even in the brain. Implications for understanding the basis and potential treatment of autoimmune conditions like multiple sclerosis, #LongCovid, #MECFS, and brain cancer.
A brief review of 6 recent, important reports
in the new Ground Truths, open-access
Such as Programming T cells with brain-specific proteins and payloads
@ScienceMagazine science.org/doi/10.1126/sc…
Or peptide fragments of myelin basic protein that suppress the immune response @Nature nature.com/articles/s4158…
New @NEJM
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated
In other GLP-1 new publications today
—Country-wide Sweden reduced hospitalizations for alcohol or substance abuse with these drugs jamanetwork.com/journals/jamap… @JAMAPsych
—Concerns about discontinuation jamanetwork.com/journals/jama/… @JAMA_current
Other new anti-obesity drugs in the pipeline, one that also increases energy expenditure
@NatureNV nature.com/articles/d4158…
A dedicated issue of @ScienceTM on #LongCovid
—Sex-specific differences, with perspective by @VirusesImmunity and @SilvaJ_C
—Insights for therapies @AndreaCoxMDPhD
—Deconvoluting "Osler's Web" @MichaelPelusoMD @DeeksSteven @DrMaureenHanson @SaydahSharon
—+RECOVER Trial, Lyme disease
An elegant @Nature study by @AkassoglouLab has illuminated our understanding of the role of fibrin (component of blood clots), #SARSCoV2, and brain inflammation in Covid and #LongCovid.
This discovery and more in the new Ground Truths podcast, with transcript, key figures (such as as the one below) and citations. Open-access. Link in my profile.
A clip from our conversation. Unknowingly, @AkassoglouLab was gearing up for understanding this complex pathophysiology for many years before Covid hit
For treatment, it's not just as simple as preventing fibrin clots. It's isolating the pro-inflammatory action of fibrin, targeted by the antibody
Covid and increased risk of major adverse cardiovascular events (MACE) 3-years out
2-fold increased for any severity of Covid
~4-fold increase for Covid requiring hospitalization
"a coronary artery disease equivalent"
interaction with non-O blood types
@uk_biobankahajournals.org/doi/10.1161/AT…
"A major finding from our analyses was that the risk
of MACE among the subset of hospitalized COVID-
19 cases without known CVD (ie, primary prevention
patients) was comparable to (or even slightly higher than) the risk in patients with CVD, PAD, or diabetes but without COVID-19."
"one of the first examples of a gene-pathogen exposure interaction for thrombotic events"
I think it's the first one documented, likely others to be unraveled
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence